InMode's Resilience Amidst Challenges: A Buy Rating With a Positive Outlook on Upcoming Product Launches and Market Recovery
Needham Maintains InMode(INMD.US) With Hold Rating
InMode's Hold Rating Amid Decelerating Growth and Economic Headwinds
Jefferies Cuts Inmode to Hold, Cites Macro Pressures
InMode Price Target Cut to $19.00/Share From $21.00 by Jefferies
InMode Analyst Ratings
InMode's Business Outlook: Maintaining a Hold Rating Amid Market Challenges and Lowered Forecasts
Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating
InMode Analyst Ratings
Canaccord Genuity Maintains Hold on InMode, Lowers Price Target to $16
InMode Analyst Ratings
InMode Analyst Ratings
Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating
InMode Analyst Ratings
InMode Analyst Ratings
InMode Analyst Ratings
Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)
InMode Analyst Ratings
Barclays Maintains Overweight on InMode, Lowers Price Target to $33
InMode Analyst Ratings